Novel Noncatalytic Substrate-Selective p38α-Specific MAPK Inhibitors with Endothelial-Stabilizing and...

Area of Science:

• Biochemistry
• Pharmacology
• Immunology

Background:

• The p38 MAPK pathway is crucial in inflammatory diseases.
• Current p38 inhibitors cause toxicity and lack specificity.
• Inhibitor failure may stem from targeting shared catalytic sites across p38 isoforms.

Purpose of the Study:

• To develop novel p38 inhibitors with improved specificity and reduced toxicity.
• To investigate a new drug design strategy targeting the substrate-docking site of p38α.
• To evaluate the efficacy of a novel compound, UM101, in preclinical models of inflammation.

Main Methods:

• Computer-aided drug design to identify compounds targeting the p38α ED substrate-docking site.
• Differential scanning fluorimetry and NMR to confirm compound binding specificity.
• RNA sequencing to analyze gene expression changes induced by UM101.
• In vivo studies using LPS-induced mouse lung injury model.

Main Results:

• UM101 demonstrated efficacy comparable to SB203580 in stabilizing endothelial barrier function and reducing inflammation.
• UM101 showed specific binding to p38α, not p38β, unlike SB203580.
• UM101 selectively inhibited a subset of inflammatory genes, sparing anti-inflammatory pathways like MSK1/2.

Conclusions:

• Targeting the ED substrate-docking site offers a promising strategy for developing selective p38 inhibitors.
• UM101 exhibits isoform specificity and substrate selectivity, suggesting potential advantages over existing p38 inhibitors.
• This approach may lead to safer and more effective treatments for inflammatory diseases.